Denali Therapeutics Inc. (DNLI) PT Lowered to $36 at Goldman Sachs, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Price: $20.75 +6.68%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 13
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $36.00 (from $37.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Clear Secure Inc (YOU) PT Raised to $80 at Goldman Sachs
- Flutter Entertainment (FLUT) PT Lowered to $124 at Stifel
- Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 74c
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
